PuSH - Publication Server of Helmholtz Zentrum München

15 Records found.
Zum Exportieren der Ergebnisse bitte einloggen.
Lay all publications on this page into basket
1.
Li, M.* ; Eckl, J. ; Geiger, C. ; Schendel, D.J. & Pohla, H.: A novel and effective method to generate human porcine-specific regulatory T cells with high expression of IL-10, TGF-β1 and IL-35. Sci. Rep. 7:3974 (2017)
2.
Lichtenegger, F.S. et al.: Next-generation dendritic cells for immunotherapy of acute myeloid leukemia. Ann. Hematol. 94, S53 (2015)
3.
Schnorfeil, F.M. et al.: Vaccination with next-generation dendritic cells for aml postremission therapy induces antigen-specific T cell responses. Eur. J. Cancer 51, S8 (2015)
4.
Schnorfeil, F.M. et al.: Dendritic cell vaccination in postremission therapy of aml: Results of a clinical phase i trial and of preclinical studies testing combinatorial approaches. Haematologica 100, 287 (2015)
5.
Lichtenegger, F.S.* et al.: Next-generation dendritic cell vaccination as postremission therapy for AML patients with a non-favorable risk profile. Haematologica 99, 435-436 (2014)
6.
Lichtenegger, F.S. et al.: Next-generation dendritic cell vaccination as postremission therapy for AML patients with a non-favorable risk profile. Oncol. Res. Treat. 37, 310 (2014)
7.
Subklewe, M. et al.: New generation dendritic cell vaccine for immunotherapy of acute myeloid leukemia. Cancer Immunol. Immunother. 63, 1093-1103 (2014)
8.
Wilde, S. et al.: Generation of allo-restricted peptide-specific T cells using RNA-pulsed dendritic cells: A three phase experimental procedure. OncoImmunology 1, 129-140 (2012)
9.
Beck, B.* et al.: Effects of TLR agonists on maturation and function of 3-day dendritic cells from AML patients in complete remission. J. Transl. Med. 9:151 (2011)
10.
Bürdek, M. et al.: Three-day dendritic cells for vaccine development: Antigen uptake, processing and presentation. J. Transl. Med. 8:90 (2010)
11.
Spranger, S. et al.: Generation of Th1-polarizing dendritic cells using the TLR7/8 agonist CL075. J. Immunol. 185, 738-747 (2010)
12.
Geiger, C. et al.: Harnessing innate and adaptive immunity for adoptive cell therapy of renal cell carcinoma. J. Mol. Med. 87, 595-612 (2009)
13.
Thirion, C.* et al.: Adenovirus vectors based on human adenovirus type 19a have high potential for human muscle-directed gene therapy. Hum. Gene Ther. 17, 193-205 (2006)
14.
Frankenberger, B. et al.: Cell-based vaccines for renal cell carcinoma: Genetically-engineered tumor cells and monocyte-derived dendritic cells. World J. Urol. 23, 166-174 (2005)
15.
Geiger, C. ; Regn, S. ; Weinzierl, A.* ; Nößner, E. & Schendel, D.J.: A generic RNA-pulsed dendritic cell vaccine strategy for renal cell carcinoma. J. Transl. Med. 3, 1-15 (2005)